Chambers Review
Provided by Chambers
USA
Healthcare: Pharmaceutical/Medical Products Regulatory - District of Columbia
Individual Editorial
Philip Katz undertakes an array of FDA matters including issues relating to orphan drugs designation and regulatory exclusivity.
Life Sciences: Regulatory/Compliance - USA - Nationwide
Individual Editorial
Philip Katz is a seasoned guide for startups and public companies in the biotech and pharmaceuticals industries, frequently assisting clients in the navigation of FDA and other regulatory frameworks. He is well versed in Hatch-Waxman, orphan drug and biosimilars issues and is adept at representing clients in court and before various regulators.
